1. Academic Validation
  2. SHANK1 facilitates non-small cell lung cancer processes through modulating the ubiquitination of Klotho by interacting with MDM2

SHANK1 facilitates non-small cell lung cancer processes through modulating the ubiquitination of Klotho by interacting with MDM2

  • Cell Death Dis. 2022 Apr 25;13(4):403. doi: 10.1038/s41419-022-04860-3.
Bo Chen 1 Hongye Zhao 1 Min Li 1 Quan She 1 Wen Liu 1 Jiayi Zhang 1 Weihong Zhao 1 Shuhong Huang 2 Jianqing Wu 3
Affiliations

Affiliations

  • 1 Department of Geriatrics, Jiangsu Provincial Key Laboratory of Geriatrics, First Affiliated Hospital, Nanjing Medical University, 210029, Nanjing, China.
  • 2 Institute of Basic Medicine, Shandong Provincial Hospital, Shandong First Medical University and Shandong Academy of Medical Sciences, 250067, Jinan, China. shuhonghuang@sdfmu.edu.cn.
  • 3 Department of Geriatrics, Jiangsu Provincial Key Laboratory of Geriatrics, First Affiliated Hospital, Nanjing Medical University, 210029, Nanjing, China. jwuny@njmu.edu.cn.
Abstract

SH3 and multiple ankyrin repeat domains 1 (SHANK1) is a scaffold protein, plays an important role in the normal function of neuron system. It has recently been shown to be a potential oncogene. In the present study, we report that the expression of SHANK1 is upregulated in non-small cell lung Cancer (NSCLC), and is correlated with clinic pathological characteristics of NSCLC. Moreover, SHANK1 overexpression enhances the proliferation, migration and invasion of NSCLC cells. Mouse cell-derived xenograft model also confirmed the effects of SHANK1 on tumor growth in vivo. Furthermore, we found that SHANK1 increases the protein degradation of Klotho (KL), an important tumor suppressor, through ubiquitination-dependent pathway. In particular, we report discovery of KL as a SHANK1-interacting protein that acts as a new substate of the E3 ubiquitin Ligase MDM2. SHANK1 can form a complex with KL and MDM2 and enhance the interaction between KL and MDM2. Our findings reveal an important oncogenic role and mechanism of SHANK1, suggesting SHANK1 can be a potential therapeutic target in NSCLC.

Figures
Products